Company / Current Liabilities
Tvardi Therapeutics, Inc. Current Liabilities History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$4.0M
FY2024
5-year range
$4.0M / $25.6M
FY2020-FY2024
Trend
-84.5%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities has fluctuated over the past 10 years, ranging from $4M in FY2024 to $43M in FY2019.
Based on SEC 10-K filings.
$4M in FY2024 with a 5-year CAGR of -37.9%.
Improved from $23M to $4M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -39.1%
- 5-Year CAGR
- -37.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -37.9%, indicating a declining trend.
- In FY2024, current liabilities decreased 84.5% year-over-year.
- Peak current liabilities was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score -6.41 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $4.0M | -84.5% |
| FY2023 | $25.6M | +9.1% |
| FY2022 | $23.5M | +33.2% |
| FY2021 | $17.6M | -4.7% |
| FY2020 | $18.5M | -56.9% |
| FY2019 | $42.9M | +6.0% |
| FY2018 | $40.4M | +375.5% |
| FY2017 | $8.5M | -26.2% |
| FY2016 | $11.5M | +118.9% |
| FY2015 | $5.3M | +55.0% |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026